341 related articles for article (PubMed ID: 33721757)
1. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
Xing NS; Fan GZ; Yan F; Liu YP; Zhang R
Int Immunopharmacol; 2021 Jun; 95():107524. PubMed ID: 33721757
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
Wang Y; Li L
Int J Rheum Dis; 2023 Feb; 26(2):225-235. PubMed ID: 36378118
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
Chartrand S; Swigris JJ; Peykova L; Fischer A
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):296-304. PubMed ID: 26847096
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in connective tissue disease-associated interstitial lung disease.
Duarte AC; Cordeiro A; Fernandes BM; Bernardes M; Martins P; Cordeiro I; Santiago T; Seixas MI; Ribeiro AR; Santos MJ
Clin Rheumatol; 2019 Jul; 38(7):2001-2009. PubMed ID: 31016581
[TBL] [Abstract][Full Text] [Related]
5. Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.
Zhao Y; Gao Y; Petnak T; Cheungpasitporn W; Thongprayoon C; Zhang X; Moua T
Respir Res; 2022 Jun; 23(1):164. PubMed ID: 35729565
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review.
Bellan M; Patrucco F; Barone-Adesi F; Gavelli F; Castello LM; Nerviani A; Andreoli L; Cavagna L; Pirisi M; Sainaghi PP
Autoimmun Rev; 2020 Feb; 19(2):102453. PubMed ID: 31838163
[TBL] [Abstract][Full Text] [Related]
7. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Maher TM; Tudor VA; Saunders P; Gibbons MA; Fletcher SV; Denton CP; Hoyles RK; Parfrey H; Renzoni EA; Kokosi M; Wells AU; Ashby D; Szigeti M; Molyneaux PL;
Lancet Respir Med; 2023 Jan; 11(1):45-54. PubMed ID: 36375479
[TBL] [Abstract][Full Text] [Related]
8. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Rituximab in Connective Tissue Disease related Interstitial Lung Disease.
Fitzgerald DB; Moloney F; Twomey M; O'Connell JO; Cronin O; Harty L; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):215-21. PubMed ID: 26422566
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease.
Sharp C; McCabe M; Dodds N; Edey A; Mayers L; Adamali H; Millar AB; Gunawardena H
Rheumatology (Oxford); 2016 Jul; 55(7):1318-24. PubMed ID: 27060110
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
Xu L; Wang F; Luo F
Front Pharmacol; 2022; 13():1019915. PubMed ID: 36386239
[No Abstract] [Full Text] [Related]
12. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
Goswami RP; Ray A; Chatterjee M; Mukherjee A; Sircar G; Ghosh P
Rheumatology (Oxford); 2021 Feb; 60(2):557-567. PubMed ID: 33164098
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases.
Vicente-Rabaneda EF; Serra López-Matencio JM; Ancochea J; Blanco R; González-Gay MÁ; Castañeda S
Expert Opin Drug Saf; 2022 Mar; 21(3):311-333. PubMed ID: 34433372
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
15. Effects of rituximab in connective tissue disorders related interstitial lung disease.
Lepri G; Avouac J; Airò P; Anguita Santos F; Bellando-Randone S; Blagojevic J; Garcia Hernàndez F; Gonzalez Nieto JA; Guiducci S; Jordan S; Limaye V; Maurer B; Selva-O'Callaghan A; Riccieri V; Distler O; Matucci-Cerinic M; Allanore Y
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):181-185. PubMed ID: 27749242
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
Borrirukwisitsak S; Tantayakom P; Katchamart W
Clin Rheumatol; 2021 Jul; 40(7):2779-2789. PubMed ID: 33428098
[TBL] [Abstract][Full Text] [Related]
17. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
[TBL] [Abstract][Full Text] [Related]
18. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD).
Jee AS; Corte TJ
Drugs; 2019 Sep; 79(14):1511-1528. PubMed ID: 31399860
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review.
Doyle TJ; Dhillon N; Madan R; Cabral F; Fletcher EA; Koontz DC; Aggarwal R; Osorio JC; Rosas IO; Oddis CV; Dellaripa PF
J Rheumatol; 2018 Jun; 45(6):841-850. PubMed ID: 29606668
[TBL] [Abstract][Full Text] [Related]
20. Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study.
Sun F; Chen J; Wu W; Geng S; Xu W; Sun S; Chen Z; Gu L; Wang X; Li T; Ye S
Clin Rheumatol; 2020 Oct; 39(10):3099-3104. PubMed ID: 32418039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
